Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) | MicrobiomeTrials← Back to trialsNCT03850964
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
CompletedPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2023-05-08Est. Completion: 2025-11-21
Enrollment target: 71 participants Locations- University of California - Los Angeles, Los Angeles, California, United States
- University of Colorado, Denver, Colorado, United States
- Augusta University, Augusta, Georgia, United States
- John Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University, St Louis, Missouri, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- University of Texas - Southwestern, Dallas, Texas, United States
- University of Utah Medical Center, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in
Hereditary Hemorrhagic Telangiectasia (HHT)Osler Weber Rendu Disease
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-b…
Phoenix, United StatesEst. completion Dec 2027
Hereditary Haemorrhagic Telangiectasia (HHT)
This observational study evaluates health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-…
Cincinnati, United StatesEst. completion Dec 2026